scispace - formally typeset
Y

Yuexin Liu

Researcher at University of Texas MD Anderson Cancer Center

Publications -  63
Citations -  27383

Yuexin Liu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 30, co-authored 62 publications receiving 19346 citations. Previous affiliations of Yuexin Liu include Baylor College of Medicine.

Papers
More filters
Journal ArticleDOI

The cancer genome atlas pan-cancer analysis project

John N. Weinstein, +379 more
- 01 Oct 2013 - 
TL;DR: The Pan-Cancer initiative compares the first 12 tumor types profiled by TCGA with a major opportunity to develop an integrated picture of commonalities, differences and emergent themes across tumor lineages.
Journal Article

The Cancer Genome Atlas Pan-Cancer analysis project

Kyle Chang, +337 more
- 01 Sep 2013 - 
TL;DR: The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels as mentioned in this paper.
Journal ArticleDOI

The Immune Landscape of Cancer

TL;DR: An extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA identifies six immune subtypes that encompass multiple cancer types and are hypothesized to define immune response patterns impacting prognosis.
Journal ArticleDOI

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Daniel J. Brat, +306 more
TL;DR: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class.
Journal ArticleDOI

Comprehensive molecular characterization of urothelial bladder carcinoma

John N. Weinstein, +296 more
- 01 Jan 2014 - 
TL;DR: Ch Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.